Authors
Latest:
Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC OptionsIn light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.
Latest:
News Reports; March 2007News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy%u2013Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck, and more
Latest:
Updated CRYSTAL Data Support Effectiveness of Cetuximab (Erbitux) in Wild-Type KRAS Metastatic Colorectal CancerAt the 2010 Gastrointestinal Cancers Symposium, new data from the CRYSTAL trial identified BRAF gene mutations as a poor prognostic indicator in metastatic colorectal cancer (mCRC) but not predictive of response to therapy.
Latest:
Working Toward a Cure in Follicular LymphomaA panel of lymphoma experts discussed 2 recently approved treatments that are providing hope to patients with relapsed or refractory follicular lymphoma.
Latest:
New Therapies for Age-Related Macular DegenerationChristina Y. Weng, MD, MBA, Baylor College of Medicine, Houston, discussed therapies for macular degeneration.
Latest:
New Study Explores Neurocognitive Outcomes Following CAR T-Cell TherapyAs patients who undergo CAR T-cell therapy survive longer, more research is required into the long-term neurocognitive effects of this treatment.
Latest:
JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer TherapyWhile the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.
Latest:
Dr. Brentjens Discusses the Goal of Armored CAR T CellsRenier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.
Latest:
Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in OncologyMiguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Latest:
Dr. Perl on CAR T Cells in Pediatric LeukemiaAlexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.
Latest:
Dr. Younes Discusses the Future of CAR T-Cell TherapyAnas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Latest:
Dr. Htut on CAR T-Cell Therapy in Patients With Multiple MyelomaMaung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.
Latest:
Dr. Sasine on CAR T-Cell Therapy in Ovarian CancerJoshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.
Latest:
Brexucabtagene Autoleucel in R/R Mantle Cell LymphomaExperts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Latest:
Lead Investigator Shares Early Data With Ibrutinib Maintenance in MCLReem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Latest:
Dr. Ostertag on Emerging CAR T Product for MyelomaEric M. Ostertag, MD, PhD, chief executive officer, Poseida Therapeutics, Inc., discusses an emerging CAR T stem cell memory product for patients with relapsed/refractory multiple myeloma.
Latest:
Monitoring and Support for Patients Receiving CAR T-Cell TherapyExperts discuss providing supportive care to patients receiving CAR T-cell therapy.
Latest:
Dr. O'Brien on CAR T Cells in CLLSusan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.
Latest:
Dr. Chari on Impact of CAR T Cells in MyelomaAjai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.
Latest:
Dr. Goy Discusses the Cost of CAR T-Cell TherapyAndre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.
Latest:
Dr. Boccia on Managing Adverse Events With CAR T-Cell TherapyRalph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.
Latest:
Dr. Cohen Discusses CAR T-Cell Therapy in MCLJonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.
Latest:
Dr. Pulsipher on MRD in Pediatric Patients Treated With CAR T CellsMichael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.
Latest:
Armin Ghobadi, MD, on Assessing CAR-T Cell Combination TherapiesThe associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.
Latest:
Dr. Summers on Role of CAR T Cells in Pediatric CancerCorinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.
Latest:
Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALLStephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALLJae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.
Latest:
Emerging Car T Therapies in Hematologic Malignancies: Jae H. Park, MDThe hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.
Latest:
Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLLSuman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).
